iTeos Therapeutics Inc
iTeos Therapeutics Inc logo
ITOS

iTeos Therapeutics Inc (ITOS)

$20.393.46%

Market is closed
– opens on 8 PM, 31 Jan 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$20.285
Day's Range
$21.31
$16.21
52-Week Range
$37.88
1 month return9.98%
3 month return4.67%
1 year return44.32%
5 year return7.03%

Analyst Recommendation

based on 11 analysts ratings

Buy
90%
Buy
9%
Hold
0%
Sell

Based on 11 Wall street analysts offering stock ratings for iTeos Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 129.28%

Current

$20.39

Target

$46.75

Recommendation Trend

Based on 11 analyst

Current1M Ago3M Ago
Buy
10
5
10
Hold
1
0
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization751.4M
Book Value$17.83
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)6.55
PE Ratio3.22
Wall Street Target Price46.75

Valuation

Trailing PE3.22
Forward PE12.56
Price/Book (mrq)1.19
Enterprise Value5.0M
Enterprise Value/Revenue0.01
Enterprise Value/Ebitda0.02

Technicals

Beta1.38
50 Day MA19.98
200 Day MA21.48

Institutional Holdings

RA Capital Management, LLC

12.42%

BlackRock Inc

12.14%

Mpm Asset Management, LLC

7.7%

Boxer Capital LLC

6.05%

State Street Corporation

5.93%

Bvf Inc

5.09%

Company Information

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of cancer immunology and immunosuppressive pathways to design novel product candidates with the potential to fully restore the immune response against cancer. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The initial antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism. An open-label Phase 1/2a clinical trial of EOS-448 is ongoing in adult cancer patients with advanced solid tumors with preliminary data indicating clinical activity as a monotherapy and a favorable tolerability profile. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression. iTeos is conducting an open-label multi-arm Phase 1/2a clinical trial of inupadenant in adult cancer patients with advanced solid tumors. Preliminary results indicate encouraging single-agent activity in the dose escalation portion of the trial. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.
OrganizationiTeos Therapeutics Inc
Employees94
CEODr. Michel Detheux Ph.D.
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is iTeos Therapeutics Inc share price today?

Can Indians buy iTeos Therapeutics Inc shares?

How can I buy iTeos Therapeutics Inc shares from India?

Can Fractional shares of iTeos Therapeutics Inc be purchased?

What are the documents required to start investing in iTeos Therapeutics Inc stocks?

What are today’s High and Low prices of iTeos Therapeutics Inc?

What are today’s traded volumes of iTeos Therapeutics Inc?

What is today’s market capitalisation of iTeos Therapeutics Inc?

What is the 52 Week High and Low Range of iTeos Therapeutics Inc?

How much percentage iTeos Therapeutics Inc is down from its 52 Week High?

How much percentage iTeos Therapeutics Inc is up from its 52 Week low?

What are the historical returns of iTeos Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of iTeos Therapeutics Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*